<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2529-850X</journal-id>
<journal-title><![CDATA[Journal of Negative and No Positive Results]]></journal-title>
<abbrev-journal-title><![CDATA[JONNPR]]></abbrev-journal-title>
<issn>2529-850X</issn>
<publisher>
<publisher-name><![CDATA[Research and Science S.L.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2529-850X2021000100010</article-id>
<article-id pub-id-type="doi">10.19230/jonnpr.3712</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Sistema renina-angiotensina (SRA) en las patologías cardiovasculares: papel sobre la hipertensión arterial]]></article-title>
<article-title xml:lang="en"><![CDATA[Renin-angiotensin system (RAS) in cardiovascular pathologies: role on arterial hypertension]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ciau-Solís]]></surname>
<given-names><![CDATA[Norma]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Betancur-Ancona]]></surname>
<given-names><![CDATA[David]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Autónoma de Yucatán Facultad de Ingeniería Química ]]></institution>
<addr-line><![CDATA[Mérida Yucatán]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2021</year>
</pub-date>
<volume>6</volume>
<numero>1</numero>
<fpage>163</fpage>
<lpage>176</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S2529-850X2021000100010&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S2529-850X2021000100010&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S2529-850X2021000100010&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción. En las patologías cardiovasculares como insuficiencia cardiaca, hipertensión arterial, vasculopatías, enfermedades coronarias, etc; el sistema renina-angiotensina (SRA) tiene participación clave, cuyas acciones principales incluyen la regulación de la presión arterial, el tono vascular, la volemia y facilitar la transmisión simpática.  Objetivo. En este ensayo se discuten estos aspectos del SRA como resultado de una secuencia de transformaciones de distintas proteínas, comenzando por la acción de la renina que transforma el angiotensinógeno en angiotensina-I y posteriormente, este se convierte en angiotensina II por acción de la enzima convertidora de angiotensina I (ECA I).  Conclusiones. Cuando este sistema se ve alterado culmina en hipertensión arterial, la cual se puede controlar mediante tratamientos farmacológicos empleando inhibidores químicos cuyos mecanismos de acción se basan en impedir que estas enzimas se unan a su sustrato y así se mantenga un equilibrio homeostático en la presión arterial.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction. In cardiovascular pathologies such as heart failure, arterial hypertension, vasculopathies, coronary diseases, etc; the renin-angiotensin system (RAS) has an essential role. The main actions include the regulation of blood pressure, vascular tone, volemia and facilitating sympathetic transmission.  Objective. This manuscript summarizes these aspects of the SRA and discussed the sequence of transformations of different proteins, beginning with the action of renin that transforms the angiotensinogen into angiotensin-I and later, it is converted into angiotensin II by the action of the Angiotensin-I converting enzyme (ACE-I).  Conclusions. When this system is altered culminates in hypertension, which can be controlled by pharmacological treatments using chemical inhibitors whose action mechanisms are based on preventing these enzymes from binding to their substrate and thus maintain a homeostatic balance in the pressure arterial.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Renina]]></kwd>
<kwd lng="es"><![CDATA[Angiotensina]]></kwd>
<kwd lng="es"><![CDATA[hipertensión]]></kwd>
<kwd lng="es"><![CDATA[inhibidores]]></kwd>
<kwd lng="en"><![CDATA[Renin]]></kwd>
<kwd lng="en"><![CDATA[Angiotensin]]></kwd>
<kwd lng="en"><![CDATA[hypertension]]></kwd>
<kwd lng="en"><![CDATA[inhibitors]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[De la Serna]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Novedades en el sistema renina-angiotensina]]></article-title>
<source><![CDATA[Insuficiencia Cardiaca]]></source>
<year>2014</year>
<volume>9</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>16-24</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nawaz]]></surname>
<given-names><![CDATA[KAA]]></given-names>
</name>
<name>
<surname><![CDATA[David]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Murugesh]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Thandeeswaran]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[GopikrishnanKiran]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Mahendran]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Identification and in silico characterization of a novel peptide inhibitor of angiotensin converting enzyme from pigeon pea (Cajanus cajan)]]></article-title>
<source><![CDATA[Phytomedicine]]></source>
<year>2017</year>
<volume>9</volume>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ponce]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Ponce]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[El sistema Renina Angiotensina desde la circulaicón hasta la célula: implicaciones más allá de la hipertensión]]></article-title>
<source><![CDATA[CorSalud]]></source>
<year>2012</year>
<volume>4</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>287-93</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kotchen]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vasculopatía hipertensiva]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Longo]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Fauci]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kasper]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Hauser]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Jameson]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Loscalzo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[HARRISON Principios de medicina interna]]></source>
<year>2012</year>
<publisher-loc><![CDATA[New York, N.Y. USA ]]></publisher-loc>
<publisher-name><![CDATA[McGraw-Hill]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ames]]></surname>
<given-names><![CDATA[MK]]></given-names>
</name>
<name>
<surname><![CDATA[Atkins]]></surname>
<given-names><![CDATA[CE]]></given-names>
</name>
<name>
<surname><![CDATA[Pitt]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The renin-angiotensin-aldosterone system and its suppression]]></article-title>
<source><![CDATA[J Vet Intern Med]]></source>
<year>2019</year>
<volume>33</volume>
<page-range>363-82</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lima]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Nuccio]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Villalobos]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Balladares]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sistema renina angiotensina y riesgo cardiometabólico]]></article-title>
<source><![CDATA[Rev. Venezolana Endocrin. Metab]]></source>
<year>2010</year>
<volume>8</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>3-10</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Macaulay]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Nnonyelum]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Angiotensin converting enzyme inhibitors]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[De Brue]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Angiotensin converting enzyme inhibitors]]></source>
<year>2009</year>
<publisher-loc><![CDATA[New York, NY, USA ]]></publisher-loc>
<publisher-name><![CDATA[Nova Science Publishers, Inc]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bader]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tissue renin-angiotensin-aldosterone systems: targets for pharmacological therapy]]></article-title>
<source><![CDATA[Annu Rev Pharmacol Toxicol]]></source>
<year>2010</year>
<volume>50</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>439-65</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bustamante]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inhibidores de renina]]></article-title>
<source><![CDATA[Rev. Peruana Cardiol]]></source>
<year>2008</year>
<volume>34</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aluko]]></surname>
<given-names><![CDATA[RE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Food protein-derived renin-inhibitory peptides: in vitro and in vivo properties]]></article-title>
<source><![CDATA[J Food Biochem]]></source>
<year>2019</year>
<volume>43</volume>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Meng]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Shao]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Yu]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aliskiren vs. other antihypertensive drugs in the treatment of hypertension: A meta-analysis]]></article-title>
<source><![CDATA[Hypertension Research]]></source>
<year>2013</year>
<volume>36</volume>
<page-range>252-61</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Morales]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Estañ]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aliskiren: el primer inhibidor directo de la renina introducido en terapéutica]]></article-title>
<source><![CDATA[Rev Esp Cardiol]]></source>
<year>2009</year>
<volume>9</volume>
<numero>^sSupl</numero>
<issue>^sSupl</issue>
<supplement>Supl</supplement>
<page-range>41A-8A</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bleakley]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Hayes]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[O&#8217;Shea]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Gallagher]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Lafarga]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Predicted release and analysis of novel ACE-I, renin, and DPP-IV inhibitory peptides from common oat (Avena sativa) protein hydrolysates using in silico analysis]]></article-title>
<source><![CDATA[Foods]]></source>
<year>2017</year>
<volume>6</volume>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Domínguez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Betancur]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Chel]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<source><![CDATA[Caracterización de la ECA-I e inhibición con péptidos alimentarios]]></source>
<year>2012</year>
<publisher-loc><![CDATA[Alemania ]]></publisher-loc>
<publisher-name><![CDATA[Editorial Académica Española]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Guang]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Phillips]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
<name>
<surname><![CDATA[Jiang]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Milani]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Three key proteases-Angiotensin-I-converting enzyme (ACE), ACE2 and Renin- within and beyond the renin-angiotensin system]]></article-title>
<source><![CDATA[Arch. Cardiovasc. Dis]]></source>
<year>2012</year>
<volume>105</volume>
<page-range>373-85</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Tao]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Peptide with angiotensin I-converting enzyme inhibitory activity from hydrolyzed corn gluten meal]]></article-title>
<source><![CDATA[J. Agric. Food Chem]]></source>
<year>2007</year>
<volume>55</volume>
<numero>19</numero>
<issue>19</issue>
<page-range>7891-5</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
